Correct Answer: C. Propranolol
Propranolol is the gold-standard prophylactic agent for migraine in patients with comorbid cardiovascular risk factors. This 35-year-old woman has a family history of coronary artery disease (CAD), making her a candidate for a beta-blocker that provides dual benefit: migraine prevention AND cardioprotection. Propranolol reduces migraine frequency by 50% in approximately 60–70% of patients through mechanisms including reduced cerebral blood flow, stabilization of serotonergic neurotransmission, and membrane-stabilizing effects. Unlike triptans (sumatriptan, naratriptan), which are acute abortive agents and contraindicated for chronic prophylaxis, propranolol is specifically indicated for long-term prevention. The presence of CAD family history is a critical discriminator: ergotamine and triptans carry vasoconstrictive risks and are contraindicated in patients with coronary risk; propranolol mitigates this risk. Topiramate, while effective for migraine prophylaxis, lacks cardioprotective properties and is not first-line in this clinical scenario. Per Indian guidelines and Harrison's recommendations, beta-blockers (propranolol, metoprolol) remain first-line prophylactic agents, especially when cardiovascular comorbidities exist. Dosing typically begins at 40–80 mg daily and titrates to 160–240 mg/day in divided doses.
Why the other options are wrong
A. Ergotamine — Ergotamine is an acute abortive agent, not a prophylactic drug, and is contraindicated in patients with CAD family history due to potent vasoconstriction and risk of coronary vasospasm. It causes ergotism with chronic use and is rarely used in modern Indian practice. NBE trap: confusing acute migraine treatment with prophylaxis. B. Topiramate — While topiramate is an effective migraine prophylactic (anticonvulsant mechanism), it lacks cardioprotective properties and is not first-line in patients with CAD risk factors. It is reserved for second-line use or when beta-blockers are contraindicated. In this patient with clear cardiovascular risk, propranolol's dual benefit makes it superior. D. Naratriptan — Naratriptan is a selective 5-HT1B/1D agonist (triptan) used for acute migraine abortion, not prophylaxis. Chronic triptan use risks medication-overuse headache and is contraindicated in patients with CAD or CAD risk factors due to coronary vasoconstriction. NBE trap: offering a triptan when prophylaxis is explicitly requested.
High-Yield Facts
- Propranolol is first-line migraine prophylaxis, especially with comorbid hypertension or CAD risk; reduces migraine frequency by 50% in 60–70% of patients.
- Triptans (sumatriptan, naratriptan) are acute abortive agents, NOT prophylactic; contraindicated in CAD/CAD risk due to coronary vasospasm.
- Ergotamine causes vasoconstriction and ergotism with chronic use; contraindicated in cardiovascular disease; rarely used in modern Indian practice.
- Topiramate (anticonvulsant) is second-line prophylaxis; effective but lacks cardioprotection; reserved for beta-blocker intolerance or failure.
- Prophylactic agents for migraine include beta-blockers (propranolol, metoprolol), tricyclic antidepressants (amitriptyline), anticonvulsants (topiramate, valproate), and calcium-channel blockers (verapamil).
Mnemonics
BETA for Migraine Prophylaxis Beta-blockers (propranolol, metoprolol) are first-line. Ergotamine is acute only. Triptans are abortive, not prophylactic. Anticonvulsants (topiramate) are second-line. Use this when choosing between prophylactic agents in a patient with cardiovascular risk. CAD Risk → Propranolol When a migraine patient has Coronary Artery Disease risk, choose Propranolol (dual cardioprotection + migraine prevention). Avoid vasoconstrictors (ergotamine, triptans).
NBE Trap
NBE pairs a triptan (sumatriptan) in the stem with migraine prophylaxis in the question to lure students into selecting another triptan (naratriptan). The key discriminator is the family history of CAD, which mandates a cardioprotective prophylactic agent (propranolol), not a vasoconstrictor.
Clinical Pearl
In Indian clinical practice, propranolol remains the most commonly prescribed migraine prophylactic because it addresses dual pathology: migraine frequency reduction AND hypertension/CAD risk mitigation—critical in a population with rising cardiovascular disease burden. A patient with family history of CAD should never receive ergotamine or chronic triptans due to coronary vasospasm risk.
_Reference: Harrison Ch. 434 (Headache); KD Tripathi Ch. 12 (Migraine Prophylaxis); Robbins Ch. 28 (Neurological Disorders)_